Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- Check3 days agoChange Detected- Updated bibliographic reference: revision changed from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedSite revision updated to v3.5.0, replacing the previous v3.4.3 revision.SummaryDifference0.0%

- Check46 days agoChange DetectedAdded the Ovarian cancer topic and a MedlinePlus Genetics related topic, and updated the revision from v3.4.2 to v3.4.3.SummaryDifference0.2%

- Check53 days agoChange DetectedOvarian cancer and the MedlinePlus Genetics related topic were removed from the page's related topics.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision: v3.4.2 was added and v3.4.1 removed; this is a minor UI revision with no impact on study content, eligibility, enrollment, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision: v3.4.1 is now shown, replacing v3.4.0. No study content or eligibility criteria appear to be changed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.